HubSpot Inc (HUBS) Stock Price Today
Aura AI Summary
Key Stats
- $11.70BMarket Cap
- 669,725Volume
- TechnologySector
- $494.5852W High
- $170.3952W Low
- 79 DaysTypical Hold Time
- $10.60BEnterprise Value
- -Div Yield
- 100% Sell | 0% BuyTrading Activity
Track HubSpot Inc (HUBS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, HubSpot Inc has traded between a low of $170.39 and a high of $494.58, highlighting its annual price range. Buy and sell HubSpot Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Most Recent News
First patient treated in clinical trial of IBA's innovative ConformalFLASH® proton therapy for head and neck cancer.
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...

WISeQey lists on Nasdaq, aims to build secure AI and satellite platform for the Intelligence Age
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...

IBA treats first patient in clinical trial for innovative ConformalFLASH® proton therapy
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.